Citadel Advisors’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $217M | Buy |
1,449,534
+673,593
| +87% | +$73.3M | 0.02% | 518 |
|
|
2026
Q1 | $71.7M | Buy |
775,941
+211,599
| +37% | +$21.2M | 0.01% | 1059 |
|
|
2025
Q4 | $57.6M | Buy |
564,342
+259,822
| +85% | +$23.2M | 0.01% | 1288 |
|
|
2025
Q3 | $19M | Sell |
304,520
-2,634,033
| -90% | -$143M | ﹤0.01% | 2405 |
|
|
2025
Q2 | $153M | Sell |
2,938,553
-658,360
| -18% | -$29.4M | 0.03% | 515 |
|
|
2025
Q1 | $153M | Buy |
3,596,913
+2,115,024
| +143% | +$91.2M | 0.03% | 477 |
|
|
2024
Q4 | $45.3M | Buy |
1,481,889
+1,151,488
| +349% | +$32.4M | 0.01% | 1361 |
|
|
2024
Q3 | $7.58M | Sell |
330,401
-2,960,496
| -90% | -$83.8M | ﹤0.01% | 3324 |
|
|
2024
Q2 | $95M | Buy |
3,290,897
+500,359
| +18% | +$11.7M | 0.02% | 711 |
|
|
2024
Q1 | $57.6M | Buy |
2,790,538
+2,762,668
| +9,913% | +$59.2M | 0.01% | 1096 |
|
|
2023
Q4 | $754K | Sell |
27,870
-410,445
| -94% | -$10.8M | ﹤0.01% | 7243 |
|
|
2023
Q3 | $13M | Buy |
438,315
+28,418
| +7% | +$999K | ﹤0.01% | 2358 |
|
|
2023
Q2 | $14.7M | Buy |
409,897
+142,831
| +53% | +$4.1M | ﹤0.01% | 2206 |
|
|
2023
Q1 | $6.26M | Sell |
267,066
-16,572
| -6% | -$473K | ﹤0.01% | 3449 |
|
|
2022
Q4 | $7.71M | Sell |
283,638
-68,214
| -19% | -$3.12M | ﹤0.01% | 3177 |
|
|
2022
Q3 | $18.9M | Buy |
351,852
+216,050
| +159% | +$11.1M | ﹤0.01% | 1929 |
|
|
2022
Q2 | $5.48M | Sell |
135,802
-398,623
| -75% | -$19.8M | ﹤0.01% | 3624 |
|
|
2022
Q1 | $35.4M | Buy |
534,425
+14,669
| +3% | +$1M | 0.01% | 1394 |
|
|
2021
Q4 | $52M | Buy |
+519,756
| New | +$53.8M | 0.01% | 1135 |
|
|
2021
Q3 | – | Sell |
-166,664
| Closed | -$19.8M | – | 14088 |
|
|
2021
Q2 | $20.7M | Sell |
166,664
-79,867
| -32% | -$10.7M | ﹤0.01% | 2033 |
|
|
2021
Q1 | $37.6M | Sell |
246,531
-38,356
| -13% | -$5.8M | 0.01% | 1296 |
|
|
2020
Q4 | $36.7M | Buy |
284,887
+44,351
| +18% | +$5.1M | 0.01% | 1215 |
|
|
2020
Q3 | $26.9M | Buy |
240,536
+178,206
| +286% | +$16.3M | 0.01% | 1324 |
|
|
2020
Q2 | $5.06M | Sell |
62,330
-64,367
| -51% | -$5.19M | ﹤0.01% | 3069 |
|
|
2020
Q1 | $8.82M | Buy |
126,697
+81,876
| +183% | +$6.28M | ﹤0.01% | 2008 |
|
|
2019
Q4 | $3.5M | Sell |
44,821
-78,024
| -64% | -$5.62M | ﹤0.01% | 3572 |
|
|
2019
Q3 | $7.84M | Buy |
122,845
+45,771
| +59% | +$4.03M | ﹤0.01% | 2520 |
|
|
2019
Q2 | $6.65M | Sell |
77,074
-15,348
| -17% | -$1.17M | ﹤0.01% | 2698 |
|
|
2019
Q1 | $7.09M | Buy |
+92,422
| New | +$5.12M | ﹤0.01% | 2499 |
|
Other funds holding GH
DTC
Citadel Advisors's GH Position: Q2 2026 in Review
Citadel Advisors increased its Guardant Health (GH) stake by 87% in Q2 2026, buying an estimated $73.3M and bringing the position to 1,449,534 shares worth $217M. The position accounts for 0.02% of the portfolio, ranked #518.
Citadel Advisors first reported a position in GH in Q1 2019 and has held it in 29 quarters since. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- Citadel Advisors held 1,449,534 shares of Guardant Health worth $217M as of Q2 2026.
- Citadel Advisors bought 673,593 Guardant Health shares in Q2 2026, an estimated $73.3M.
- Guardant Health made up 0.02% of Citadel Advisors's portfolio in Q2 2026, its #518 holding.
- Citadel Advisors first reported a position in Guardant Health in Q1 2019 and has held it in 29 quarters since.
- 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.